943 related articles for article (PubMed ID: 26026669)
1. Input of molecular analysis in medical management of primary brain tumor patients.
Idbaih A; Duran-Peña A; Bonnet C; Ducray F
Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of gliomas: potential therapeutic implications.
Alentorn A; Duran-Peña A; Pingle SC; Piccioni DE; Idbaih A; Kesari S
Expert Rev Anticancer Ther; 2015; 15(8):955-62. PubMed ID: 26118895
[TBL] [Abstract][Full Text] [Related]
3. Treatment of anaplastic glioma.
Wick W; Wiestler B; Platten M
Cancer Treat Res; 2015; 163():89-101. PubMed ID: 25468227
[TBL] [Abstract][Full Text] [Related]
4. Predictive biomarkers in adult gliomas: the present and the future.
Thomas L; Di Stefano AL; Ducray F
Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
[TBL] [Abstract][Full Text] [Related]
5. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
Michotte A; Neyns B; Chaskis C; Sadones J; In 't Veld P
Acta Neurol Belg; 2004 Dec; 104(4):148-53. PubMed ID: 15742604
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic and predictive factors for gliomas in adults].
Frenel JS; Botti M; Loussouarn D; Campone M
Bull Cancer; 2009 Apr; 96(4):357-67. PubMed ID: 19357011
[TBL] [Abstract][Full Text] [Related]
7. [OMICS and biomarkers of glial tumors].
Idbaih A
Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
[TBL] [Abstract][Full Text] [Related]
8. Pathological classification of brain tumors.
Pollo B
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):103-11. PubMed ID: 22617234
[TBL] [Abstract][Full Text] [Related]
9. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract][Full Text] [Related]
10. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
11. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
12. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
13. [Multidisciplinar approach to the management of gliomas].
Moura B; Migliorini D; Bourhis J; Daniel R; Levivier M; Hottinger AF
Rev Med Suisse; 2016 Apr; 12(516):821-5. PubMed ID: 27281939
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetics of gliomas.
Appin CL; Brat DJ
Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and prognosis of gliomas--current prospects of molecular diagnostics].
Haapasalo J; Hyartt A; Salmi M; Nordfors K; Lahtela SL; Kähkönen M; Helén P; Haapasalo H
Duodecim; 2014; 130(9):893-901. PubMed ID: 24881141
[TBL] [Abstract][Full Text] [Related]
16. Molecular predictors of outcome in low-grade glioma.
Weiler M; Wick W
Curr Opin Neurol; 2012 Dec; 25(6):767-73. PubMed ID: 23160425
[TBL] [Abstract][Full Text] [Related]
17. Molecularly based management of gliomas in clinical practice.
Rudà R; Pellerino A; Magistrello M; Franchino F; Pinessi L; Soffietti R
Neurol Sci; 2015 Sep; 36(9):1551-7. PubMed ID: 26194534
[TBL] [Abstract][Full Text] [Related]
18. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Taylor JW; Chi AS; Cahill DP
Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
[TBL] [Abstract][Full Text] [Related]
19. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
20. [Histological and molecular classification of gliomas].
Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
